Epizyme gains on latest tazemetostat readout in NHL

Epizyme Inc. (NASDAQ:EPZM) gained $1.20 (11%) to $12.35 on Wednesday as investors digested updated results from a Phase II trial of tazemetostat (EPZ-6438) in patients with relapsed or refractory diffuse large

Read the full 311 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE